Long-term therapy and symptomatic treatment of neuromyelitis optica spectrum disorders
Authors:
M. Vachová 1,2
Authors‘ workplace:
Neurologické oddělení s RS centrem, Nemocnice Teplice o. z. – Krajská, zdravotní a. s.
1; Neurologická klinika a Centrum klinických, neurověd, 1. LF UK a VFN v Praze
2
Published in:
Cesk Slov Neurol N 2020; 83/116(supplementum 1): 62-67
doi:
https://doi.org/10.14735/amcsnn2020S62
Overview
The recognition of pathogenetic mechanisms of neuromyelitis optica spectrum disorders (NMOSD) led to the development of new drugs targeting these processes. Those drugs minimize the risk of relapses of the disease. Instead of original empiric therapeutic procedures, new placebo--controlled double-blinded clinical trials were finished and their results were published. Three new drugs, eculizumab, inebilizumab and satralizumab, with a different mode of action are coming to the market for patients with AQP4-IgGpos NMOSD. The insight into their mode of action and potential adverse events are essential for their use. The article shows long term management of NMOSD including the symptomatic care.
Keywords:
management of NMOSD – long-term therapy – eculizumab – inebilizumab – satralizumab
Sources
1. Wingerchuk DM, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2): 177–189. doi: 10.1212/WNL.0000000000001729.
2. Borisow N, Mori M, Kuwabara S. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 2018; 9: 888. doi: 10.3389/fneur.2018.00888.
3. Palace J, Leite MI, Nairne A et al. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67 (8): 1016–1017. doi: 10.1001/archneurol.2010.188.
4. Kleiter I, Hellwig K, Berthele A et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69 (2): 239–245. doi: 10.1001/archneurol.2011.216.
5. Wagner F, Grunder L, Hakim A et al. Rebound After fingolimod and a single daclizumab injection in a patient retrospectively diagnosed with NMO spectrum disorder-MRI apparent diffusion coefficient maps in differential diagnosis of demyelinating CNS disorders. Front Neurol 2018; 9: 782. doi: 10.3389/fneur.2018.00782.
6. Azzopardi L, Cox AL, McCarthy CL et al. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016; 263 (1): 25–29. doi: 10.1007/s00415-015-7925-y.
7. Trebst C, Jarius S, Berthele A et al. Update on the diag-nosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014; 261 (1): 1–16. doi: 10.1007/s00415-013-7169-7.
8. Havrdová E. Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího širšího spektra. [online]. Dostupné z URL: https: //www.czech-neuro.cz/pro-odborniky/doporucene-postupy/klinicke-standardy/klinicky-doporuceny-postup-pro-diagnostiku-a-lecbu-roztrousene-sklerozy-a-neuromyelitis-optica-a-onemocneni-jejiho-sirsiho-spektra.
9. Havrdová E et al. Roztroušená skleróza. In: Nytrová P (ed). Léčba pacientů s neruomyelitis optica a poruchami širšího spektra neuromyelitis optica. Praha: Mladá fronta 2013: 363–367.
10. Zahra N, Shervin B, Shaygannejad V et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264 (9): 2003–2009. doi: 10.1007/s00415-017-8590-0.
11. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016; 73 (11): 1342–1348. doi: 10.1001/jamaneurol.2016.1637.
12. Ciron J, Audoin B, Bourre B et al. Recommendations for the use of rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris) 2018; 174 (4): 255–264. doi: 10.1016/j.neurol.2017.11.005.
13. Hinson SR, Lennon VA, Pittock SJ et al. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handb Clin Neurol 2016; 133: 377–403. doi: 10.1016/B978-0-444-63432-0.00021-9.
14. Jacob A, Matiello M, Weinshenker BG et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66 (9): 1128–1133. doi: 10.1001/archneurol.2009.175.
15. Minagar A, Sheremata W. Treatment of Devic‘s disease with methotrexate and prednisone. Int J MS Care 2000; 2 (4): 43–49. doi: 10.7224/1537-2073-2.4.43.
16. Araki M, Aranami T, Matsuoka T et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013; 23 (4): 827–831. doi: 10.1007/s10165-012-0715-9.
17. Thomas TC, Rollins SA, Rother RP et al. Inhibition of complement activity by humanized anti-C5 antibody and singlechain Fv. Mol Immunol 1996; 33 (17–18): 1389–1401. doi: 10.1016/s0161-5890 (96) 00078-8.
18. Pittock SJ, Berthele A, Fujihara K et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381 (7): 614–625. doi: 10.1056/NEJMoa1900866.
19. Cree BA, Bennett JL, Kim HJ et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorde (N-MOmentum): a double-blind, randomised placebo--controlled phase 2/3 trial. Lancet 2019; 394 (10206): 1352–1363. doi: 10.1016/S0140-6736 (19) 31817-
20. Yamura T, Kleiter I, Fujihara K et al, Trial of Satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381 (22): 2114–2124. doi: 10.1056/NEJMoa1901747.
21. Raboulsee A, Greenberg BM, Bennett JL et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19 (5): 402–412. doi: 10.1016/S1474-4422 (20) 30078.
22. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 2016; 18 (1): 2. doi: 10.1007/s11940-015-0387-9.
23. Clerc C, Bertrand B, Bereau M et al. Dalfampridine for symptomatic treatment of neuromyelitis optica (P5.263). Neurology 2015; 84 (14 Supplement): P5.263.
Labels
Paediatric neurology Neurosurgery NeurologyArticle was published in
Czech and Slovak Neurology and Neurosurgery
2020 Issue supplementum 1
Most read in this issue
- Magnetic resonance imaging in neuromyelitis optica spectrum disorders
- Neuromyelitis optica spectrum disorders – laboratory examination
- Epidemiology, clinical manifestation, and disease course of neuromyelitis optica spectrum disorders
- Differential diagnosis of neuromyelitis optica spectrum disorders